Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of$ 0.34. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.76%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.32 per share when it actually produced a loss of $0.35, delivering a surprise of -9.38%.Over the last four quarters, the ...